Glembatumumab

Glembatumumab is a fully human IgG2 monoclonal antibody directed against the extracellular structural domain of GPNMB expressed in human breast cancer and melanoma. Glembatumumab can be coupled to the microtubule inhibitor monomethyl auristatin E to form glembatumumab vedotin. Glembatumumab vedotin is an antibody-agent coupling (ADC) with antitumor activity[1].

Product Specifications

CAS Number

[1020264-78-1]

UNSPSC

12352203

Target

ADC Antibody

Type

Inhibitory Antibodies

Related Pathways

Antibody-drug Conjugate/ADC Related

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/glembatumumab.html

Purity

99.69

Solubility

10 mM in DMSO

Smiles

[Glembatumumab]

Molecular Weight

(145.56 kDa)

References & Citations

[1]Naumovski L, et al. Glembatumumab vedotin, a conjugate of an anti-glycoprotein non-metastatic melanoma protein B mAb and monomethyl auristatin E for the treatment of melanoma and breast cancer. Curr Opin Mol Ther. 2010 Apr;12 (2) :248-57.|[2]E Anders Kolb, et al. Initial testing (stage 1) of glembatumumab vedotin (CDX-011) by the pediatric preclinical testing program. Pediatr Blood Cancer. 2014 Oct;61 (10) :1816-21.|[3]Xiaozhong Qian, et al. Pharmacologically enhanced expression of GPNMB increases the sensitivity of melanoma cells to the CR011-vcMMAE antibody-drug conjugate. Mol Oncol. 2008 Jun;2 (1) :81-93.